MCOA Subsidiaries to Exhibit at the Las Vegas Champs Trade Show

Marijuana Company of America, Inc. (OTC PINK:MCOA) ('the Company'), a diversified holding company with operations and investments throughout the cannabis industry, today announced that its wholly owned subsidiaries hempSmart ™ and cDistro, will be exhibiting at the 2021 Champs Trade Show in Las Vegas being held July 27-30, 2021 at the Las Vegas Convention Center

Recently acquired MCOA asset cDistro, distributes CBD brands, along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America, and will be featuring the new Marley One™ product line, the first global functional mushroom consumer brand, licensed and distributed by Silo Wellness Inc. ('SiloWellness') (CSE:SILO)(OTCQB:SILFF)(FRA:3K70), a leading global psychedelics company. The product offering includes a range of functional mushroom tinctures, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement.

“We anticipate large volume sales with this strong brand recognition associated with Bob Marley Family name,” said Ron Russo, President of cDistro.

hempSmart ™, MCOA's other wholly owned subsidiary will be at the Champs Trade Show exhibiting its extensive full line of premium CBD organic products that are scientifically driven and double lab tested to ensure purity and potency.

“We are thrilled to be part of this premier cannabis trade show and this opportunity could not have come at a better time with the rapid expansion and vertical integration that has recently taken place at MCOA, coupled with the excitement of showcasing together for the first time our premium hempSmart ™ brands alongside the plethora of cannabis product offerings from our recently acquired cDistro distributor,” said Jesus Quintero, CEO of Marijuana Company of America, Inc.

MCOA also indicated that its Joint Venture Partner, Cannabis Global Inc. (OTC PINK:CBGL) will be exhibiting alongside the Company.

Russo added, “This Champs Trade Show will allow MCOA executives and subsidiaries to meet with prominent people, retailers, and other companies in the cannabis space. The event offers us the opportunity to network with retailers, and other leaders in the industry as well afford us the chance to showcase our newest product Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family.”

“hempSmart ™ will be featuring many exciting products and features at the Champs Trade Show, such as a product redesign and our new mental health check text messaging community service called ‘we're in this together.' We want our brand to reach beyond our physical product in a new impactful manner never before seen by other CBD companies. We're building a community of support and resources for our customers to take advantage of,” said Glen Bonilla, Sales Director and Brand Manager of hempSmart ™.

Bonilla added, “With our recent expansion of our hempSMART™ branded product lines and marketing channels, we look ahead with great enthusiasm as we showcase our products at the Champs Trade Show, which will be the first time selling directly to retailers. We have continued to receive wonderful responses about our premium CBD products from satisfied consumers sharing their success stories of overall improvement in leading a more positive lifestyle. Hearing this positive feedback from people who buy our products is so fulfilling and there's no better feeling than knowing we are making a difference in the lives of our customers.”

MCOA also indicated that its Joint Venture Partner, Cannabis Global Inc. (OTC PINK:CBGL) will be exhibiting alongside the Company.

To see MCOA, Cdistro , hempSmart ™, and Cannab is Global Inc. at the 2021 Champs Trade Show, please visit booth #1042.

About CHAMPS Trade Show

Champs has established itself as the premier counter-culture, business-to-business trade expo serving the smoke shop industry.

Since 1999, hundreds of exhibitors meet across the country each year face-to-face with thousands of retail and wholesale buyers from all over the world at CHAMPS Trade Shows.

CHAMPS exhibitors include manufacturers, distributors, wholesalers, glass artists, inventors, and suppliers who showcase a massive selection of smoking accessories, counter-culture products, clothing, hand-blown glass, and other specialty gifts.

About Marijuana Company of America, Inc. (OTC PINK:MCOA)

Marijuana Company of America is a diversified holding company with operations and investments throughout the cannabis industry. MCOA focuses on acquisitions, as well as sales and marketing efforts of its wholly owned subsidiaries cDistro Distributor and hempsmart™ premium brand of hemp-based CBD (legal cannabidiol) products.

About hempSMART

hempSMART™ offers an extensive full line of premium CBD organic products that are scientifically driven and double lab tested to ensure purity and potency. The Company will direct the sale of its products to wholesalers, distributors, the medical community, online e-commerce consumer platforms, and a proven network affiliate marketing program. The Company has also launched international sales, production, and marketing expansion.

About cDistro

cDistro (Retail Service / Wholesale Prices) distributes CBD brands, along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America.

About Silo Wellness

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE:SILO) and Frankfurt (FRA:CK70) exchanges and trading on the OTCQB® Venture Market (OTCQB:SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.marleyone.com.

For more information about Silo Wellness, please visit www.silowellness.com.

Forward-Looking Statements

This news release contains 'forward-looking statements,' which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as 'anticipate,' 'seek,' 'intend,' 'believe,' 'estimate,' 'expect,' 'project,' 'plan,' or similar phrases may be deemed 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic reports filed from time to time with the Securities and Exchange Commission.

For more information, please visit www.marijuanacompanyofamerica.com or visit www.sec.gov.

CONTACT:
info@marijuanacompanyofamerica.com
info@mcoainvestments.com
888-777-4362

SOURCE: Marijuana Company of America, Inc.

View source version on accesswire.com:
https://www.accesswire.com/656896/MCOA-Subsidiaries-to-Exhibit-at-the-Las-Vegas-Champs-Trade-Show

News Provided by ACCESSWIRE via QuoteMedia

Silo Wellness CSE:SILO Psychedelics Investing

Albert Labs Validates Global Supply Chain for Controlled Substances

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50), the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical company bringing innovative prescription medicines to patients with unmet mental health needs, is pleased to announce the validation of their controlled substance supply chain through the successful global distribution of its psilocybin-based KRN Active Pharmaceutical Ingredient (API).

Albert Labs have successfully distributed their proprietary KRN API from their Health Canada licensed laboratory in Vancouver . Only very few companies have the ability to globally distribute controlled substances of this classification, Schedule 1. This now enables the API to be used as part of their pre-clinical studies at its Infarmed licensed laboratory in Porto, Portugal . This distribution follows an extensive research and development programme allowing for the production and scaling of highly potent yields of its KRN API, for which IP protection has been achieved, using bioreactor technology to ensure the efficient and economical manufacture of its mycelium derived pharmaceutical product.

The company is nearing completion of their KRN-101 pre-clinical studies, which includes full analytical profiling, in-vivo, and in-vitro studies, allowing the medicine to be used in its first, in-human studies in Melbourne, Australia due to begin in Q2 2023 .

Dr. Michael Raymont , CEO of Albert Labs : "Validating our supply chain across two of our jurisdictions, North America and Europe , marks a valuable milestone in our operational program. We have demonstrated our ability to distribute KRN-101, a schedule 1 substance, to global, licensed facilities, and this achievement advances our progress by establishing the viability of our supply chain as we prepare for our first-in-human studies."

Business of Albert Labs International Corp.

Albert Labs is a fully-integrated biopharmaceutical company bringing innovative prescription medicines to patients with unmet mental health needs. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognised clinical route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines.

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

The company's goal is to deliver effective medicines to those who suffer with their mental health in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.

Albert Labs (CSE: ABRT) (FSE: VB50) is publicly listed on the Canadian Securities Exchange (CSE) .

You can find more details about Albert Labs on our website here .

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer, Chairman

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.

The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.

Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

SOURCE Albert Labs International Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2023/15/c5639.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today it has entered into an agreement with a life sciences-focused investment fund for the sale of 12,059,298 shares of its common stock, pre-funded warrants exercisable for an aggregate of 9,340,702 shares of common stock and common warrants exercisable for an aggregate of 26,750,000 shares of common stock. The shares of common stock and accompanying common warrants are being sold at a combined offering price of $0.525 per share, and the pre-funded warrants and accompanying common warrants are being sold at a combined offering price of $0.524 per pre-funded warrant. All of the shares of common stock, pre-funded warrants and accompanying warrants to be sold in the offering will be sold by Seelos. The pre-funded warrants will be immediately exercisable following the closing of the offering and will have an exercise price of $0.001 per share. The common warrants will not be exercisable until after the six-month anniversary of the closing of the offering, will have an exercise price of $0.60 per share and will expire on the date that is five and a half years following the closing of the offering.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows:

Cowen 43 ^rd Annual Health Care Conference: ‘Neuropsych Panel' at 12:50pm ET on March 6, 2023 and host investor meetings
Oppenheimer 33 ^rd Annual Healthcare Conference: presentation at 10:00am ET on March 13, 2023 and host investor meetings
Loop Capital Conference: host investor meetings on March 14, 2023

Live audio webcast of the panel and presentation will be accessible from the "Events" page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Highlights:

Phase 3 pivotal program underway - important updates announced
Phase 3 long term follow up defined
Cash position at 31 December 2022 of $143.2 million
Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business.

Kabir Nath, Chief Executive Officer, said, "During this past quarter, we commenced our COMP360 phase 3 pivotal program in treatment-resistant depression, a significant milestone for our area of science as these are the first ever phase 3 trials of psilocybin. We have also announced important updates to this program that accelerate the placebo-controlled trial pivotal data read out and streamline the long-term follow up as an integrated component of the pivotal trials. We are confident that this phase 3 program should generate the evidence to support a regulatory filing and to support broad patient access through integration into healthcare systems."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

	December 31,
	2022	2021
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$ 143,206	$ 273,243
Restricted cash	175	104
Prepaid income tax	575	332
Prepaid expenses and other current assets	47,695	21,621
Total current assets	191,651	295,300
NON-CURRENT ASSETS:
Investment	469	525
Property and equipment, net	617	398
Operating lease right-of-use assets	2,006	3,696
Deferred tax assets	2,224	766
Other assets	327	213
Total assets	$ 197,294	$ 300,898
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$ 4,761	$ 2,564
Accrued expenses and other liabilities	9,325	10,308
Operating lease liabilities - current	1,510	2,235
Total current liabilities	15,596	15,107
NON-CURRENT LIABILITIES
Operating lease liabilities - non-current	418	1,379
Total liabilities	16,014	16,486

Commitments and contingencies (Note 15)
SHAREHOLDERS' EQUITY:
Ordinary shares, £0.008 par value; 42,631,794 and 42,019,874 shares authorized, issued and outstanding at December 31, 2022 and 2021, respectively	440	435
Deferred shares, £21,921.504 par value; one share authorized, issued and outstanding at December 31, 2022 and 2021	28	28
Additional paid-in capital	458,825	444,750
Accumulated other comprehensive (loss)/income	(16,867)	8,840
Accumulated deficit	(261,146)	(169,641)
Total shareholders' equity	181,280	284,412
Total liabilities and shareholders' equity	$ 197,294	$ 300,898

	Three Months Ended December 31,		Twelve Months Ended December 31,
	2022	2021	2022	2021
OPERATING EXPENSES:
Research and development	$19,794	$13,593	$65,053	$44,027
General and administrative	12,397	14,730	45,350	39,194
Total operating expenses	32,171	28,323	110,403	83,221
LOSS FROM OPERATIONS:	(32,191)	(28,323)	(110,403)	(83,221)
OTHER INCOME (EXPENSE), NET:
Other income, net	481	38	4,061	40
Foreign exchange gains (losses)	(3,566)	(181)	821	1,990
Benefit from R&D tax credit	4,442	2,915	14,424	9,648
Total other income (expense), net	1,357	2,772	19,306	11,678
Loss before income taxes	(30,834)	(25,551)	(91,097)	(71,543)
Income tax expense	(92)	(99)	(408)	(199)
Net loss	(30,926)	(25,650)	(91,505)	(71,742)
Other comprehensive loss:
Foreign exchange translation adjustment	13,776	1,076	(25,707)	(5,745)
Comprehensive loss	(17,150)	(24,574)	(117,212)	(77,487)
Net loss per share attributable to ordinary shareholders—basic and diluted	$(0.73)	$(0.61)	$(2.16)	$(1.79)
Weighted average ordinary shares outstanding—basic and diluted	42,436,292	39,997,587	42,436,292	39,997,587

WESTERN COPPER AND GOLD ANNOUNCES STRATEGIC INVESTMENT BY MITSUBISHI MATERIALS CORPORATION

Psychedelics Investing News

MCOA Subsidiaries to Exhibit at the Las Vegas Champs Trade Show

Silo Wellness

Overview

Company Highlights

Business Segments

Psilocybin Metered-Dose Nasal Spray

Psychedelic Wellness Retreats

Management Team

Mike Arnold - Founder, CEO, Oregon lawyer

Winfield Ding - Chief Financial Officer, CPA, CGA

Michael Hartman - Director, Psilocybin Nasal

Dr. Parag Bhatt, Ph.D - Pharmacologist Science Advisor

Dr. Simon Bababeygy - Director, M.D.

Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Albert Labs Validates Global Supply Chain for Controlled Substances

Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!

Psilocin is the key for Lobe Sciences

Regulatory Hurdles are Falling

Contact Details

Company Website

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Latest Press Releases

CORRECTION FROM SOURCE: Strathmore Plus Uranium Engages Gold Standard Media Amended

Silver Viper Closes Additional Tranche of Private Placement

Alkaline Fuel Cell Power Corp. Announces Grant of Restricted Share Units and Corporate Update

Strathmore Plus Uranium Engages Gold Standard Media

Related News

Top Stories This Week: Gold Price Breaks US$2,000 Twice, Fed Hikes Again

Brunswick Exploration Announces Closing of First Tranche of Non-Brokered Private Placement

Trailbreaker Resources: Grassroots Exploration with Blue-Sky Potential

Heritage Mining Announces Early Issuance of Exploration Permit for Flagship Project Drayton Black Lake

Laramide Resources Ltd. Announces Results from the Diamond Drilling Program at its Crownpoint-Churchrock Uranium Project, New Mexico, U.S.A.

Orefinders Plans to Update TSXV Listing Status to a Mining & Investment Issuer

Brisbane Mining Conference

TOP STOCKS